Quarterly ResultMay 4, 2026, 08:53 AM
Organon Q1 Net Income Jumps to $146M, EPS $0.55; Revenue $1.46B
AI Summary
Organon & Co. reported a significant increase in net income to $146 million and diluted EPS to $0.55 for the first quarter of 2026, up from $87 million and $0.33 respectively in the prior year, despite a slight decrease in revenues to $1,460 million. The company divested its Jada System for up to $465 million, recording an $81 million gain, and entered a new licensing agreement for Miudella®2 with Sebela Pharmaceuticals, involving an upfront payment of $27.5 million and potential milestones up to $505 million. Additionally, Organon implemented restructuring initiatives, reducing headcount by approximately 3%, and saw a substantial improvement in net cash flows from operating activities.
Key Highlights
- Net income increased to $146 million in Q1 2026 from $87 million in Q1 2025.
- Diluted EPS rose to $0.55 in Q1 2026 from $0.33 in Q1 2025.
- Revenues decreased to $1,460 million in Q1 2026 from $1,513 million in Q1 2025.
- Divested the Jada System for up to $465 million, recognizing an $81 million gain.
- Entered exclusive license agreement with Sebela for Miudella®2, with $27.5 million upfront and up to $505 million in milestones.
- Net cash flows from operating activities increased to $225 million from $75 million.
- Implemented restructuring initiatives resulting in an approximate 3% headcount reduction.
- Cash and cash equivalents increased to $1,116 million from $574 million at year-end 2025.